D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

In COPD, muscular atrophy is a significant risk factor for death and may prolong patients’ hospital length of stay.

The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has reported positive Phase 2 trial results for ATH434, its lead candidate for ...

Three Australian companies will be presenting at Sharecafe's "Sip & Learn" webinar today—Nico Resources, Immutep, and ...